Literature DB >> 29758087

Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma.

V Haug1, V Behle1, S Benoit1, H Kneitz1, B Schilling1, M Goebeler1, A Gesierich1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29758087     DOI： 10.1111/bjd.16780

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  8 in total

1.  Efficacy and safety of tetracyclines for pemphigoid: a systematic review and meta-analysis.

Authors:  Xin-Xing Jin; Xue Wang; Ying Shan; Si-Zhe Li; Qun Xu; Hong-Zhong Jin; Ya-Gang Zuo
Journal:  Arch Dermatol Res       Date:  2021-03-28       Impact factor: 3.017

Review 2.  Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response.

Authors:  Enrico Zelin; Carlo Alberto Maronese; Arianna Dri; Ludovica Toffoli; Nicola Di Meo; Gianluca Nazzaro; Iris Zalaudek
Journal:  J Clin Med       Date:  2022-06-11       Impact factor: 4.964

Review 3.  Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.

Authors:  Chieh-Hsun Chen; Hsin-Su Yu; Sebastian Yu
Journal:  Curr Oncol       Date:  2022-04-18       Impact factor: 3.109

4.  Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature.

Authors:  Coralie Zumelzu; Marina Alexandre; Christelle Le Roux; Patricia Weber; Alexis Guyot; Annie Levy; Françoise Aucouturier; Sabine Mignot-Grootenboer; Frédéric Caux; Eve Maubec; Catherine Prost-Squarcioni
Journal:  Front Med (Lausanne)       Date:  2018-09-27

Review 5.  Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases.

Authors:  Yoshiaki Yura; Masakazu Hamada
Journal:  Cancers (Basel)       Date:  2022-02-04       Impact factor: 6.639

Review 6.  Immune checkpoint inhibitors to treat cutaneous malignancies.

Authors:  Dulce M Barrios; Mytrang H Do; Gregory S Phillips; Michael A Postow; Tomoko Akaike; Paul Nghiem; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2020-05-24       Impact factor: 11.527

7.  A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder.

Authors:  Xiaoxiao Wang; Mariano Suppa; Pascal Bruderer; Nicolas Sirtaine; Sandrine Aspeslagh; Joseph Kerger
Journal:  Case Rep Oncol       Date:  2021-06-15

8.  Paraneoplastic Pemphigus Revealed by Anti-programmed Death-1 Pembrolizumab Therapy for Cutaneous Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa.

Authors:  Ahmad Yatim; Gérôme Bohelay; Sabine Grootenboer-Mignot; Catherine Prost-Squarcioni; Marina Alexandre; Christelle Le Roux-Villet; Antoine Martin; Eve Maubec; Frédéric Caux
Journal:  Front Med (Lausanne)       Date:  2019-11-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.